Pediatrix Medical Group, Inc. (MD) P/E Ratio History
UndervaluedTrading at 12.1x vs 5Y avg 20.2x · 40th percentile · Below historical baseline · Data 1996–2026
Loading P/E history...
P/E Ratio Analysis
As of June 23, 2026, Pediatrix Medical Group, Inc. (MD) trades at a price-to-earnings ratio of 12.1x, with a stock price of $23.52 and trailing twelve-month earnings per share of $2.10.
The current P/E is 40% below its 5-year average of 20.2x. Over the past five years, MD's P/E has ranged from a low of 8.9x to a high of 129.2x, placing the current valuation at the 40th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.1x, MD trades at a 45% discount to its sector peers. The sector includes 233 companies with P/E ratios ranging from 0.0x to 194.5x.
Relative to the broader market, MD trades at a notable discount to the S&P 500 median P/E of 24.3x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our MD DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
MD Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
MD P/E vs Peers
Physician platforms and value-based care peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $16B | 11.5 | 0.34Best | -53% | |
| $590M | 12.7 | - | -15% | |
| $84B | 13.3 | 0.63 | +29% | |
| $9B | 6.2 | 0.38 | +37% | |
| $428M | 0.8Lowest | - | +197%Best | |
| $2B | 14.0 | - | -29% | |
| $369B | 30.7 | - | -15% | |
| $129B | 72.9 | - | -62% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
MD Historical P/E Data (1996–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q1 | - | $21.39 | $2.05 | 10.4x | -62% |
| FY2025 Q4 | Dec 31 2025 | $21.39 | $1.93 | 11.1x | -59% |
| FY2025 Q3 | - | $16.75 | $1.88 | 8.9x | -67% |
| FY2025 Q2 | Jun 30 2025 | $14.35 | $1.27 | 11.3x | -58% |
| FY2023 Q3 | Sep 30 2023 | $12.71 | $1.13 | 11.2x | -58% |
| FY2023 Q2 | Jun 30 2023 | $14.21 | $1.24 | 11.5x | -58% |
| FY2023 Q1 | Mar 31 2023 | $14.91 | $1.22 | 12.2x | -55% |
| FY2022 Q4 | Dec 31 2022 | $14.86 | $0.80 | 18.6x | -31% |
| FY2022 Q3 | Sep 30 2022 | $16.51 | $0.99 | 16.7x | -38% |
| FY2022 Q2 | - | $21.01 | $0.98 | 21.4x | -21% |
| FY2022 Q1 | - | $23.48 | $1.07 | 21.9x | -19% |
| FY2021 Q4 | Dec 31 2021 | $27.21 | $1.53 | 17.8x | -34% |
| FY2021 Q3 | - | $28.43 | $0.22 | 129.2x | +377% |
| FY2018 Q4 | Dec 31 2018 | $33.00 | $2.93 | 11.3x | -58% |
| FY2018 Q3 | Sep 30 2018 | $46.66 | $3.70 | 12.6x | -53% |
| FY2018 Q2 | Jun 30 2018 | $43.28 | $3.69 | 11.7x | -57% |
| FY2018 Q1 | Mar 31 2018 | $55.63 | $3.53 | 15.8x | -42% |
| FY2017 Q4 | Dec 31 2017 | $53.44 | $3.44 | 15.5x | -43% |
| FY2017 Q3 | Sep 30 2017 | $43.12 | $2.82 | 15.3x | -44% |
| FY2017 Q2 | Jun 30 2017 | $60.37 | $3.15 | 19.2x | -29% |
| FY2017 Q1 | Mar 31 2017 | $69.38 | $3.35 | 20.7x | -24% |
| FY2016 Q4 | Dec 31 2016 | $66.66 | $3.49 | 19.1x | -30% |
| FY2016 Q3 | Sep 30 2016 | $66.25 | $3.65 | 18.2x | -33% |
| FY2016 Q2 | - | $72.43 | $3.58 | 20.2x | -25% |
| FY2016 Q1 | - | $64.62 | $3.59 | 18.0x | -34% |
| FY2015 Q4 | - | $71.66 | $3.58 | 20.0x | -26% |
| FY2015 Q3 | Sep 30 2015 | $76.79 | $3.48 | 22.1x | -19% |
| FY2015 Q2 | - | $74.11 | $3.37 | 22.0x | -19% |
| FY2015 Q1 | - | $72.51 | $3.26 | 22.2x | -18% |
| FY2014 Q4 | Dec 31 2014 | $66.11 | $3.17 | 20.9x | -23% |
| FY2014 Q3 | - | $54.82 | $3.06 | 17.9x | -34% |
| FY2014 Q2 | Jun 30 2014 | $58.15 | $2.96 | 19.6x | -28% |
| FY2014 Q1 | Mar 31 2014 | $61.98 | $2.85 | 21.7x | -20% |
| FY2013 Q4 | - | $53.38 | $2.77 | 19.3x | -29% |
| FY2013 Q3 | Sep 30 2013 | $50.20 | $2.65 | 18.9x | -30% |
| FY2013 Q2 | Jun 30 2013 | $45.79 | $2.55 | 18.0x | -34% |
| FY2013 Q1 | Mar 31 2013 | $44.81 | $2.48 | 18.1x | -33% |
| FY2012 Q4 | Dec 31 2012 | $39.76 | $2.42 | 16.4x | -39% |
| FY2012 Q3 | Sep 30 2012 | $37.23 | $2.36 | 15.8x | -42% |
| FY2012 Q2 | Jun 30 2012 | $34.27 | $2.30 | 14.9x | -45% |
| FY2012 Q1 | Mar 31 2012 | $37.19 | $2.26 | 16.5x | -39% |
| FY2011 Q4 | Dec 31 2011 | $36.01 | $2.24 | 16.1x | -41% |
| FY2011 Q3 | Sep 30 2011 | $31.32 | $2.20 | 14.2x | -47% |
| FY2011 Q2 | - | $36.09 | $2.25 | 16.0x | -41% |
| FY2011 Q1 | - | $33.30 | $2.20 | 15.1x | -44% |
| FY2010 Q4 | Dec 31 2010 | $33.65 | $2.14 | 15.7x | -42% |
| FY2010 Q3 | - | $26.65 | $2.12 | 12.6x | -54% |
| FY2010 Q2 | Jun 30 2010 | $27.80 | $1.99 | 14.0x | -48% |
| FY2010 Q1 | Mar 31 2010 | $29.09 | $1.94 | 15.0x | -45% |
| FY2009 Q4 | - | $30.05 | $1.90 | 15.8x | -42% |
| FY2009 Q3 | Sep 30 2009 | $27.46 | $1.79 | 15.3x | -43% |
| FY2009 Q2 | - | $21.07 | $1.68 | 12.5x | -54% |
| FY2009 Q1 | - | $14.73 | $1.60 | 9.2x | -66% |
| FY2008 Q4 | Dec 31 2008 | $15.85 | $1.80 | 8.8x | -68% |
| FY2008 Q3 | - | $26.96 | $1.80 | 15.0x | -45% |
| FY2008 Q2 | Jun 30 2008 | $24.61 | $1.79 | 13.8x | -49% |
| FY2008 Q1 | Mar 31 2008 | $33.70 | $1.76 | 19.1x | -29% |
| FY2007 Q4 | Dec 31 2007 | $34.08 | $1.45 | 23.5x | -13% |
| FY2007 Q3 | Sep 30 2007 | $32.71 | $1.36 | 24.1x | -11% |
| FY2007 Q2 | Jun 30 2007 | $27.57 | $1.32 | 20.9x | -23% |
| FY2007 Q1 | Mar 31 2007 | $28.53 | $1.30 | 21.9x | -19% |
| FY2006 Q4 | Dec 31 2006 | $24.45 | $1.29 | 19.0x | -30% |
| FY2006 Q3 | Sep 30 2006 | $22.80 | $1.11 | 20.5x | -24% |
| FY2006 Q2 | Jun 30 2006 | $22.65 | $1.04 | 21.8x | -20% |
| FY2006 Q1 | Mar 31 2006 | $25.66 | $0.98 | 26.2x | -3% |
| FY2005 Q4 | Dec 31 2005 | $22.14 | $0.92 | 24.1x | -11% |
| FY2005 Q3 | Sep 30 2005 | $19.20 | $1.04 | 18.5x | -32% |
| FY2005 Q2 | - | $18.39 | $1.01 | 18.2x | -33% |
| FY2005 Q1 | - | $17.15 | $0.98 | 17.5x | -35% |
| FY2004 Q4 | Dec 31 2004 | $16.01 | $1.00 | 16.0x | -41% |
| FY2004 Q3 | - | $13.71 | $0.97 | 14.1x | -48% |
| FY2004 Q2 | Jun 30 2004 | $17.46 | $0.95 | 18.4x | -32% |
| FY2004 Q1 | Mar 31 2004 | $15.75 | $0.91 | 17.3x | -36% |
| FY2003 Q4 | Dec 31 2003 | $13.77 | $0.87 | 15.8x | -42% |
| FY2003 Q3 | - | $11.51 | $0.81 | 14.2x | -48% |
| FY2003 Q2 | Jun 30 2003 | $8.91 | $0.75 | 11.9x | -56% |
| FY2003 Q1 | Mar 31 2003 | $6.29 | $0.70 | 9.0x | -67% |
| FY2002 Q4 | - | $10.02 | $0.66 | 15.2x | -44% |
| FY2002 Q3 | Sep 30 2002 | $7.75 | $0.57 | 13.6x | -50% |
| FY2002 Q2 | Jun 30 2002 | $6.25 | $0.49 | 12.8x | -53% |
| FY2002 Q1 | Mar 31 2002 | $10.19 | $0.41 | 25.2x | -7% |
| FY2001 Q4 | Dec 31 2001 | $8.48 | $0.33 | 25.7x | -5% |
| FY2001 Q3 | Sep 30 2001 | $10.20 | $0.29 | 34.7x | +28% |
| FY2001 Q2 | Jun 30 2001 | $8.30 | $0.25 | 32.7x | +21% |
| FY2001 Q1 | Mar 31 2001 | $5.55 | $0.17 | 31.8x | +17% |
| FY2000 Q4 | Dec 31 2000 | $6.02 | $0.17 | 34.5x | +27% |
| FY2000 Q3 | Sep 30 2000 | $3.22 | $0.19 | 16.9x | -38% |
| FY2000 Q2 | Jun 30 2000 | $2.91 | $0.17 | 17.1x | -37% |
| FY2000 Q1 | Mar 31 2000 | $1.81 | $0.30 | 5.9x | -78% |
| FY1999 Q4 | Dec 31 1999 | $1.75 | $0.31 | 5.7x | -79% |
| FY1999 Q3 | - | $3.47 | $0.36 | 9.7x | -64% |
| FY1999 Q2 | Jun 30 1999 | $5.31 | $0.35 | 15.3x | -43% |
| FY1999 Q1 | Mar 31 1999 | $7.03 | $0.24 | 28.8x | +6% |
| FY1998 Q4 | - | $14.98 | $0.21 | 70.3x | +159% |
| FY1998 Q3 | Sep 30 1998 | $11.22 | $0.13 | 83.2x | +207% |
| FY1998 Q2 | - | $9.30 | $0.13 | 73.0x | +170% |
| FY1998 Q1 | - | $11.63 | $0.12 | 98.5x | +264% |
| FY1997 Q4 | Dec 31 1997 | $10.69 | $0.11 | 96.7x | +257% |
| FY1997 Q3 | - | $11.03 | $0.09 | 120.6x | +345% |
| FY1997 Q2 | Jun 30 1997 | $11.45 | $0.08 | 136.3x | +403% |
| FY1997 Q1 | Mar 29 1997 | $8.69 | $0.08 | 110.0x | +306% |
| FY1996 Q4 | - | $9.25 | $0.07 | 125.0x | +361% |
| FY1996 Q3 | Sep 30 1996 | $12.53 | $0.09 | 146.6x | +441% |
Average P/E for displayed period: 27.1x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
30+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
MD — Frequently Asked Questions
Quick answers to the most common questions about buying MD stock.
What is MD's P/E ratio?
Pediatrix Medical Group, Inc. (MD) trailing twelve-month P/E ratio is 12.1x, based on TTM diluted EPS of $2.10. The 5-year average P/E is 20.2x and the historical range spans 8.9x to 129.2x.
Is MD stock overvalued or undervalued?
MD trades at 12.1x P/E, below its 5-year average of 20.2x. At the 40th percentile of its historical range (8.9x–129.2x), the stock is priced at a discount to its own history.
Is MD stock expensive?
No, MD is not expensive on a historical basis. The current P/E of 12.1x is below the 5-year average of 20.2x and sits at the 40th percentile of its valuation range.
What is MD's historical P/E range?
Over the past 5 years, MD's P/E ratio has ranged from 8.9x to 129.2x, with a median of 15.3x and an average of 20.2x. The current P/E of 12.1x places the stock at the 40th percentile of this range. Full historical data spans 1996–2026.
How does MD's P/E compare to the S&P 500?
MD trades at 12.1x P/E versus the S&P 500 median of 24.3x. The 50% discount to the market suggests lower growth expectations or perceived higher risk.
How does MD's valuation compare to Healthcare peers?
Pediatrix Medical Group, Inc. P/E of 12.1x compares to the Healthcare sector median of 22.1x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is MD's PEG ratio?
MD PEG ratio is N/A, based on a P/E of 12.1x and EPS growth of 263.0%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is MD's earnings yield?
MD earnings yield is 8.25%, the inverse of its 12.1x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.